Rein Therapeutics Receives FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
Phase 2 RENEW trial underway; interim data expected in H2 2026.
/ 2 items
Phase 2 RENEW trial underway; interim data expected in H2 2026.
Maxim highlights reduced risk and strong progress on LTI-03 for idiopathic pulmonary fibrosis. Phase 2 RENEW trial underway with topline data expected by end of 2027.